Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 696

1.
2.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
3.

Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?

Schawo S, van der Kolk A, Bouwmans C, Annemans L, Postma M, Buitelaar J, van Agthoven M, Hakkaart-van Roijen L.

Pharmacoeconomics. 2015 May;33(5):489-509. doi: 10.1007/s40273-015-0259-x.

4.

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.

Can J Clin Pharmacol. 2006 Winter;13(1):e50-62. Epub 2006 Jan 23.

5.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

6.

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G.

Pediatrics. 2001 Oct;108(4):883-92.

PMID:
11581440
7.

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.

Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

PMID:
16389216
8.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Pharmacoeconomics. 2012 Aug 1;30(8):e1-15. doi: 10.2165/11632920-000000000-00000.

9.
10.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

11.

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.

Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R.

Eur Child Adolesc Psychiatry. 2005 Sep;14(6):297-304.

PMID:
16220213
12.

National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS.

J Clin Psychiatry. 2008 Jan;69(1):131-40.

PMID:
18312048
13.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
14.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
15.

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M.

Clin Ther. 2001 Nov;23(11):1904-21.

PMID:
11768842
16.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
17.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
18.

Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.

Donnelly M, Haby MM, Carter R, Andrews G, Vos T.

Aust N Z J Psychiatry. 2004 Aug;38(8):592-601.

PMID:
15298581
19.
20.

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.

Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.

Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.

PMID:
21904084
Items per page

Supplemental Content

Write to the Help Desk